KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for NovoCure (NVCR) over the last 11 years, with Q3 2025 value amounting to 0.33%.

  • NovoCure's Return on Capital Employed fell 100.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.39% for FY2024, which is 1500.0% down from last year.
  • According to the latest figures from Q3 2025, NovoCure's Return on Capital Employed is 0.33%, which was down 100.0% from 0.35% recorded in Q2 2025.
  • In the past 5 years, NovoCure's Return on Capital Employed registered a high of 0.04% during Q1 2021, and its lowest value of 0.36% during Q4 2024.
  • For the 5-year period, NovoCure's Return on Capital Employed averaged around 0.17%, with its median value being 0.19% (2024).
  • As far as peak fluctuations go, NovoCure's Return on Capital Employed soared by 300bps in 2021, and later plummeted by -1600bps in 2023.
  • Quarter analysis of 5 years shows NovoCure's Return on Capital Employed stood at 0.04% in 2021, then plummeted by -95bps to 0.09% in 2022, then plummeted by -175bps to 0.24% in 2023, then plummeted by -49bps to 0.36% in 2024, then increased by 7bps to 0.33% in 2025.
  • Its Return on Capital Employed stands at 0.33% for Q3 2025, versus 0.35% for Q2 2025 and 0.33% for Q1 2025.